Guanghai Dai

889 total citations
34 papers, 670 citations indexed

About

Guanghai Dai is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Guanghai Dai has authored 34 papers receiving a total of 670 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 16 papers in Surgery. Recurrent topics in Guanghai Dai's work include Gastric Cancer Management and Outcomes (19 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (11 papers) and Pancreatic and Hepatic Oncology Research (8 papers). Guanghai Dai is often cited by papers focused on Gastric Cancer Management and Outcomes (19 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (11 papers) and Pancreatic and Hepatic Oncology Research (8 papers). Guanghai Dai collaborates with scholars based in China, United States and Switzerland. Guanghai Dai's co-authors include Yan Shi, Quanli Han, Jinwan Wang, Rui‐Hua Xu, Shukui Qin, Jianming Xu, Huan Yan, Yunpeng Liu, Lixin Wei and Yao Lv and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Guanghai Dai

33 papers receiving 661 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Guanghai Dai China	13	359	354	183	168	125	34	670
Izuma Nakayama Japan	14	527 1.5×	450 1.3×	214 1.2×	123 0.7×	103 0.8×	108	820
Akiko Kawano Nagatsuma Japan	12	381 1.1×	387 1.1×	153 0.8×	164 1.0×	126 1.0×	16	653
Marta Martín-Richard Spain	17	483 1.3×	238 0.7×	190 1.0×	150 0.9×	46 0.4×	42	708
Fabiola Lorena Rojas Llimpe Italy	10	500 1.4×	498 1.4×	217 1.2×	117 0.7×	135 1.1×	32	791
Takeo Kosaka Japan	15	219 0.6×	420 1.2×	322 1.8×	95 0.6×	208 1.7×	85	769
Hong Jo Choi South Korea	12	276 0.8×	174 0.5×	177 1.0×	148 0.9×	52 0.4×	25	546
Fernando Rivera Spain	13	331 0.9×	372 1.1×	174 1.0×	157 0.9×	92 0.7×	27	612
Kotaro Hirashima Japan	14	234 0.7×	270 0.8×	296 1.6×	192 1.1×	39 0.3×	29	643
M Starnawski Austria	3	466 1.3×	660 1.9×	271 1.5×	195 1.2×	268 2.1×	5	862

Countries citing papers authored by Guanghai Dai

Since Specialization

Citations

This map shows the geographic impact of Guanghai Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guanghai Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guanghai Dai more than expected).

Fields of papers citing papers by Guanghai Dai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guanghai Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guanghai Dai. The network helps show where Guanghai Dai may publish in the future.

Co-authorship network of co-authors of Guanghai Dai

This figure shows the co-authorship network connecting the top 25 collaborators of Guanghai Dai. A scholar is included among the top collaborators of Guanghai Dai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guanghai Dai. Guanghai Dai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Shiyun, Zhao-Li Tan, Yanli Lin, et al.. (2025). miR-196b strictly regulates and reliably predicts the response to cetuximab in colorectal cancer. Cellular & Molecular Biology Letters. 30(1). 64–64.

Gou, Miaomiao, Yong Zhang, Zhikuan Wang, Niansong Qian, & Guanghai Dai. (2024). PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study. Investigational New Drugs. 42(2). 171–178. 9 indexed citations

Chen, Shiyun, Zhao-Li Tan, Yanli Lin, et al.. (2024). Single‐cell sequencing analysis reveals cetuximab resistance mechanism and salvage strategy in colorectal cancer. Clinical and Translational Medicine. 15(1). e70151–e70151. 2 indexed citations

Huang, Lei, Xiaodong Yuan, Quanli Han, et al.. (2023). Gene signature developed for predicting early relapse and survival in early-stage pancreatic cancer. BJS Open. 7(3). 10 indexed citations

Liu, Qu, Guodong Zhao, Xiuping Zhang, et al.. (2021). Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. Langenbeck s Archives of Surgery. 407(2). 633–643. 7 indexed citations

Xu, Rui‐Hua, Zhi‐Qiang Wang, Lin Shen, et al.. (2019). S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.. Journal of Clinical Oncology. 37(15_suppl). 4017–4017. 15 indexed citations

Li, Wanwan, et al.. (2019). Pretreatment platelet to lymphocyte ratio is predictive of overall survival in metastatic pancreatic ductal adenocarcinoma. Translational Cancer Research. 8(1). 17–22. 6 indexed citations

Xu, Rui‐Hua, Feng Wang, Xiaoli Wei, et al.. (2019). Tumor mutational burden identifies chemorefractory gastric cancer with overall survival advantage after receiving toripalimab, a PD-1 antibody.. Journal of Clinical Oncology. 37(15_suppl). 4021–4021. 3 indexed citations

Chen, Yang, et al.. (2019). CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer. BMC Cancer. 19(1). 860–860. 9 indexed citations

10.

Wang, Yanrong, Yang Chen, Hongyan Yin, et al.. (2018). Timing of chemotherapy‐induced neutropenia is a prognostic factor in patients with advanced gastric cancer undergoing first‐line chemotherapy with oxaliplatin and capecitabine: a retrospective study. Cancer Medicine. 7(4). 997–1005. 10 indexed citations

11.

Han, Quanli, et al.. (2017). Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature‐based meta‐analysis. Journal of Clinical Pharmacy and Therapeutics. 43(2). 163–169. 16 indexed citations

12.

Lv, Yao, Yan Shi, Quanli Han, & Guanghai Dai. (2017). Histone demethylase PHF8 accelerates the progression of colorectal cancer and can be regulated by miR-488 in vitro. Molecular Medicine Reports. 16(4). 4437–4444. 22 indexed citations

13.

Yang, Chen, et al.. (2017). Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma. Scientific Reports. 7(1). 753–753. 50 indexed citations

14.

Yu, Xiaoling, Ping Liang, Zhigang Cheng, et al.. (2016). Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: Preliminary results and literature review. International Journal of Hyperthermia. 32(5). 524–530. 5 indexed citations

15.

Shen, Lin, Zhihao Lü, Tianshu Liu, et al.. (2015). 144O Comparison of efficacy and safety of paclitaxel and capecitabine followed by capecitabine as maintenance therapy versus cisplatin and capecitabine therapy for advanced gastric cancer: a multicentre, randomised, active-controlled phase III study. Annals of Oncology. 26. ix42–ix42. 1 indexed citations

16.

Chen, Li, Yan Shi, Jing Yuan, et al.. (2014). HIF-1 Alpha Overexpression Correlates with Poor Overall Survival and Disease-Free Survival in Gastric Cancer Patients Post-Gastrectomy. PLoS ONE. 9(3). e90678–e90678. 56 indexed citations

17.

Chen, Li, Yan Shi, Jing Yuan, et al.. (2014). Evaluation of docetaxel- and oxaliplatin-based adjuvant chemotherapy in postgastrectomy gastric cancer patients reveals obvious survival benefits in docetaxel-treated mixed signet ring cell carcinoma patients. Medical Oncology. 31(9). 159–159. 26 indexed citations

18.

Shen, Lin, Jin Li, Jianming Xu, et al.. (2014). Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 18(1). 168–176. 184 indexed citations

19.

Dai, Guanghai, et al.. (2012). Trastuzumab Combined with Docetaxel-Based Regimens in Previously Treated Metastatic Gastric Cancer Patients with HER2 Over-Expression. Hepatogastroenterology. 59(120). 2439–44. 12 indexed citations

20.

Shi, Yan, et al.. (2011). Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma. European Journal of Surgical Oncology. 37(6). 513–520. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact